Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...

US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...

The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to ...

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...

UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...

French drugmaker Ipsen (Euronext: IPN) announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

USA-based Paratek Pharmaceuticals has released positive top-line data from a Phase IIb trial evaluating its oral antibiotic ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Zai Lab has priced its public offering at $25.50 per share, targeting $200 million for corporate purposes. The fundraising ...

South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty ...